GlassScriptPhysician profile
Sara N Karnes
NPI 1174150023
$5,096.25
in general payments reported to CMS, 2019-2025
17 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $1,459 · 2023: $1,003 · 2024: $946 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.79 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,123.34 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $693.62 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $638.44 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $592.92 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $390.75 | 2023-2025 | Spravato, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $386.74 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $322.99 | 2023-2025 | Ingrezza |
| Tris Pharma INC | $230.33 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Axsome Therapeutics, INC. | $200.19 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $134.42 | 2023 | Quviviq |
| Lundbeck LLC | $99.62 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $78.19 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $68.90 | 2025 | Cobenfy |
| Indivior INC. | $57.10 | 2023-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $41.78 | 2025 | Qelbree |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $19.03 | 2025 | Erzofri Extended-Release |
| Genentech USA, INC. | $17.89 | 2023 | Ocrevus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Karnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.